ProKidney Corp. is a Pharma company based in the USA with an ESG score of 27.8, indicating a medium risk level. Specializing in clinical-stage biotechnology, ProKidney has a unique cell therapy platform that utilizes a patient's own cells to treat various chronic kidney diseases. Their lead product, REACT (Renal Autologous Cell Therapy), has the potential to delay the progression of kidney disease. The company's pipeline includes a development program focused on severe diabetic kidney disease.